Breast Surgery — MCQs

Breast Surgery Indian Medical PG Practice Questions and MCQs

Question 141: Bleeding from the nipple is seen in which of the following conditions?

A. Mastitis
B. Breast carcinoma (Correct Answer)
C. Mammary dysplasia
D. Eczema

Explanation: **Explanation:** Nipple discharge is a common clinical presentation in breast surgery. When the discharge is **bloody (sanguineous)**, it is most frequently associated with **Intraductal Papilloma** (the most common cause overall) or **Breast Carcinoma** (the most concerning cause). In the context of the provided options, Breast Carcinoma is the definitive pathological condition where malignant erosion of the ductal epithelium leads to bleeding. **Analysis of Options:** * **Breast Carcinoma (Correct):** Approximately 5-10% of patients with breast cancer present with nipple discharge. It is typically spontaneous, unilateral, and arises from a single duct. In older women, bloody discharge is highly suspicious for Ductal Carcinoma in Situ (DCIS) or invasive papillary carcinoma. * **Mastitis:** This is an inflammation/infection of the breast tissue, usually associated with lactation. It typically presents with pain, fever, and purulent (pus-like) discharge, not frank bleeding. * **Mammary Dysplasia (Fibrocystic Breast Disease):** This condition usually presents with cyclical mastalgia and lumpy breasts. Discharge, if present, is typically serous (straw-colored) or greenish, but rarely bloody. * **Eczema:** Eczema of the nipple/areola causes itching, redness, and scaling. While it may cause serous oozing or crusting due to excoriation, it does not cause discharge from the milk ducts themselves. (Note: Persistent "eczema" that does not heal should raise suspicion for Paget’s disease of the breast). **Clinical Pearls for NEET-PG:** * **Most common cause of bloody nipple discharge:** Intraductal Papilloma. * **Most common cause of nipple discharge overall:** Duct ectasia (presents with multicolored/thick discharge). * **Triple Assessment:** Any suspicious nipple discharge must be evaluated via clinical examination, imaging (Mammography/Ultrasound), and cytology/biopsy. * **Management:** For single-duct discharge, **Microdochectomy** (removal of the involved duct) is the diagnostic and therapeutic procedure of choice.

Question 142: Regarding breast cancer, all are true except?

A. It increases with increasing age.
B. Medullary cancer has the poorest prognosis. (Correct Answer)
C. Involvement of subdermal lymphatics carries a bad prognosis.
D. It has an increased incidence with estrogen exposure.

Explanation: **Explanation:** The correct answer is **B**, as Medullary carcinoma of the breast is actually associated with a **favorable prognosis** compared to the more common Invasive Ductal Carcinoma (NOS), despite often being high-grade and "triple-negative." **1. Why Option B is the "Except" (Correct Answer):** Medullary carcinoma typically presents in younger patients (often associated with BRCA1 mutations). Histologically, it shows high-grade nuclei and a dense lymphocytic infiltrate. Despite these aggressive features, it has a better 10-year survival rate than standard infiltrating ductal carcinomas. The **poorest prognosis** in breast cancer is generally associated with **Inflammatory Breast Cancer** or **Metaplastic Carcinoma.** **2. Analysis of Other Options:** * **Option A:** Risk increases with age. The incidence of breast cancer rises significantly after age 40, with the majority of cases occurring in postmenopausal women. * **Option B:** Involvement of subdermal lymphatics leads to **Peau d'orange**, a hallmark of Inflammatory Breast Cancer (T4d). This signifies advanced disease and carries a very poor prognosis. * **Option D:** Prolonged estrogen exposure (early menarche, late menopause, HRT, or nulliparity) is a well-established risk factor for the development of breast cancer. **High-Yield Clinical Pearls for NEET-PG:** * **Most common type:** Invasive Ductal Carcinoma (NOS). * **Best prognosis:** Tubular and Mucinous (Colloid) carcinomas. * **Molecular Subtypes:** Luminal A has the best prognosis; Basal-like (Triple Negative) has a poor prognosis. * **Sentinel Lymph Node Biopsy (SLNB):** The gold standard for axillary staging in clinically node-negative (cN0) patients. * **Paget’s Disease of the Nipple:** Associated with an underlying DCIS or invasive carcinoma in >95% of cases.

Question 143: Estrogen receptor (ER) and progesterone receptor (PR) status is used as a prognostic variable in which of the following cancers?

A. Carcinoma of the breast (Correct Answer)
B. Carcinoma of the ovary
C. Carcinoma of the endometrium
D. Carcinoma of the cervix

Explanation: **Explanation:** In **Carcinoma of the Breast**, the expression of Estrogen Receptors (ER) and Progesterone Receptors (PR) is a critical **prognostic and predictive factor**. * **Prognostic value:** Patients with ER/PR positive tumors generally have a better prognosis, lower grade of malignancy, and longer disease-free survival compared to receptor-negative tumors. * **Predictive value:** It determines the response to endocrine therapy (e.g., Tamoxifen or Aromatase Inhibitors). Approximately 80% of ER+ tumors respond to hormonal manipulation. **Analysis of Incorrect Options:** * **B. Carcinoma of the Ovary:** While some ovarian cancers express ER/PR, they are not routinely used as standard prognostic variables or to guide primary treatment protocols in the same way as breast cancer. * **C. Carcinoma of the Endometrium:** Although ER/PR status can be measured and correlates with tumor grade, it is not the primary prognostic variable used in clinical staging or standard management (which relies more on FIGO stage, depth of invasion, and histology). * **D. Carcinoma of the Cervix:** This is primarily associated with Human Papillomavirus (HPV) infection. ER/PR status has no established prognostic or therapeutic role here. **High-Yield Clinical Pearls for NEET-PG:** 1. **Triple Negative Breast Cancer (TNBC):** Tumors lacking ER, PR, and HER2/neu. These carry the **worst prognosis** and do not respond to hormonal or anti-HER2 therapy. 2. **Luminal A subtype:** (ER+, PR+, HER2-, low Ki-67) has the **best prognosis**. 3. **Allred Scoring:** Used by pathologists to quantify ER/PR expression based on the proportion of stained cells and intensity. 4. **HER2/neu:** A transmembrane glycoprotein (tyrosine kinase) that, when overexpressed, indicates a more aggressive tumor but predicts response to **Trastuzumab**.

Question 144: When galactorrhea occurs in a high school student, which of the following is an associated diagnostic finding?

A. Gonadal atrophy
B. Bitemporal hemianopia (Correct Answer)
C. Exophthalmos and lid lag
D. Episodic hypertension

Explanation: **Explanation:** The clinical presentation of galactorrhea in a young patient (high school student) most commonly points toward **Hyperprolactinemia**. The most frequent pathological cause of significantly elevated prolactin levels is a **Prolactinoma** (a pituitary adenoma). **1. Why Bitemporal Hemianopia is Correct:** As a pituitary adenoma (especially a macroadenoma, >10mm) grows, it expands superiorly out of the sella turcica and exerts pressure on the **optic chiasm**, which lies directly above it. This compression damages the decussating nasal retinal fibers, leading to the classic visual field defect known as **bitemporal hemianopia** (loss of the outer half of the vertical visual field in both eyes). **2. Analysis of Incorrect Options:** * **A. Gonadal atrophy:** While hyperprolactinemia causes hypogonadotropic hypogonadism (leading to amenorrhea or infertility), it typically does not cause gross anatomical "atrophy" of the gonads in the acute/subacute setting. * **C. Exophthalmos and lid lag:** These are hallmark signs of **Graves' disease** (hyperthyroidism). While hypothyroidism can cause galactorrhea (via increased TRH stimulating prolactin), hyperthyroidism does not. * **D. Episodic hypertension:** This is the classic presentation of **Pheochromocytoma**, a catecholamine-secreting tumor of the adrenal medulla, which has no direct association with galactorrhea. **High-Yield Clinical Pearls for NEET-PG:** * **Drug-induced galactorrhea:** Always rule out dopamine antagonists (e.g., Metoclopramide, Haloperidol, Risperidone) as they are the most common non-physiological cause. * **Hook Effect:** In cases of extremely large prolactinomas, lab results may show falsely low prolactin levels; serial dilution is required for accurate measurement. * **Treatment of Choice:** Medical management with **Dopamine agonists** (Cabergoline > Bromocriptine) is the first-line treatment for prolactinomas, even for large tumors, as they effectively shrink the mass and restore vision. Surgery (Transsphenoidal) is reserved for refractory cases.

Question 145: Where are Rotter's lymph nodes located?

A. Infraclavicular region
B. Mediastinum
C. Supraclavicular region
D. Interpectoral region (Correct Answer)

Explanation: **Explanation:** **Rotter’s lymph nodes**, also known as **interpectoral nodes**, are a specific group of lymph nodes located between the **pectoralis major** and **pectoralis minor** muscles. In the surgical management of breast cancer, these nodes are considered part of the **Level II** axillary lymph nodes. * **Why Option D is correct:** By definition, Rotter's nodes reside in the interpectoral fascia. They serve as a potential pathway for direct lymphatic drainage from the breast to the higher axillary levels (Level III), bypassing Levels I and II. * **Why Options A & C are incorrect:** The **infraclavicular nodes** are classified as **Level III** axillary nodes (located medial/superior to the pectoralis minor), while **supraclavicular nodes** are considered N3 disease (distant metastasis) in the TNM staging of breast cancer, located above the clavicle. * **Why Option B is incorrect:** The **mediastinum** contains internal mammary nodes (medial drainage), but Rotter’s nodes are strictly associated with the axillary drainage system. **High-Yield Clinical Pearls for NEET-PG:** * **Berg’s Levels of Axillary Nodes:** * **Level I:** Lateral to pectoralis minor. * **Level II:** Deep to pectoralis minor (includes **Rotter’s nodes**). * **Level III:** Medial to pectoralis minor. * **Surgical Significance:** During a Modified Radical Mastectomy (MRM), if Rotter’s nodes are palpably enlarged, the interpectoral fascia must be cleared to ensure complete oncological resection. * **Drainage:** They receive lymph directly from the mammary gland and drain into Level II and III nodes.

Question 146: What is the first investigation to be done in a lactating woman with a painful breast?

A. Ultrasound (USG) (Correct Answer)
B. Mammography
C. CT scan
D. MRI

Explanation: **Explanation:** The correct answer is **Ultrasound (USG)**. In a lactating woman presenting with a painful breast, the most common clinical concern is **Lactational Mastitis** or a **Breast Abscess**. **Why USG is the first investigation:** 1. **Safety:** USG involves no ionizing radiation, making it safe for both the mother and the nursing infant. 2. **Diagnostic Accuracy:** It is the gold standard for differentiating between simple mastitis (cellulitis) and a breast abscess (fluid collection). If an abscess is present, USG can guide needle aspiration for both diagnosis and treatment. 3. **Breast Density:** Lactating breasts are physiologically dense due to glandular hyperplasia. USG is far superior to mammography in visualizing lesions within dense breast tissue. **Why other options are incorrect:** * **Mammography:** It is difficult to interpret in lactating women due to high parenchymal density (low sensitivity). Furthermore, the compression required is extremely painful in an acutely inflamed breast and carries a risk of radiation. * **CT Scan:** It is not a primary modality for breast imaging. It lacks the resolution for detailed breast anatomy and involves significant radiation. * **MRI:** While highly sensitive, it is expensive, time-consuming, and unnecessary for diagnosing common inflammatory conditions like mastitis or abscesses. **Clinical Pearls for NEET-PG:** * **Triple Assessment:** Clinical examination, Imaging (USG <35 yrs; Mammography >35 yrs), and Pathology (FNAC/Biopsy). * **Management:** For a lactational abscess, **ultrasound-guided needle aspiration** is now preferred over traditional Incision and Drainage (I&D) as it allows for continued breastfeeding and results in less scarring. * **Breastfeeding:** Patients should be encouraged to **continue breastfeeding** from the affected breast to prevent milk stasis, unless there is frank pus draining from the nipple.

Question 147: What is the use of injecting Methylene Blue dye in breast cancer surgery?

A. Tattooing for biopsy
B. Marking of tumor cells
C. Sentinel lymph node biopsy (Correct Answer)
D. Photodynamic therapy

Explanation: ### Explanation **Correct Answer: C. Sentinel lymph node biopsy (SLNB)** **Mechanism and Concept:** Sentinel Lymph Node Biopsy (SLNB) is the standard of care for axillary staging in clinically node-negative (cN0) breast cancer. The "Sentinel Node" is the first lymph node(s) to receive lymphatic drainage from the primary tumor. In this procedure, **Methylene Blue** (or Isosulfan Blue/Patent Blue) is injected periareolarly or subdermally. The dye travels through the lymphatic channels to the axilla, staining the afferent lymphatics and the sentinel node(s) blue, allowing the surgeon to identify and excise them for pathological examination. This avoids the morbidity of a full Axillary Lymph Node Dissection (ALND) if the nodes are negative. **Analysis of Incorrect Options:** * **A. Tattooing for biopsy:** While dyes can be used to mark skin, "tattooing" in breast surgery usually refers to placing a metallic clip or carbon suspension to mark a tumor site post-neoadjuvant chemotherapy, not Methylene Blue. * **B. Marking of tumor cells:** Methylene Blue is a lymphatic tracer, not a tumor-specific marker. It does not selectively stain malignant cells within the breast parenchyma. * **D. Photodynamic therapy:** This involves photosensitizing agents (like porphyrins) and specific light wavelengths to destroy cancer cells. Methylene Blue is not the standard agent for breast cancer PDT. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Technique:** The highest identification rate for SLNB is achieved using a combination of **Radioactive Technetium-99m (Sulfur Colloid)** and **Blue Dye**. * **Contraindication:** SLNB is generally avoided in inflammatory breast cancer. * **Side Effect:** Patients should be warned that Methylene Blue can cause a temporary greenish-blue discoloration of urine and skin. * **Safety:** Isosulfan blue carries a small risk of anaphylaxis (approx. 1%); Methylene Blue is a safer, cost-effective alternative often used in resource-limited settings.

Question 148: What is the annual risk of developing breast cancer detected by mammography?

A. 1% (Correct Answer)
B. 0.01%
C. 2%
D. 2.50%

Explanation: **Explanation:** The correct answer is **1% (Option A)**. This figure refers to the **cancer detection rate** in asymptomatic women undergoing routine screening mammography. In a standard screening population (women aged 40–70), approximately 10% of mammograms are flagged as abnormal, necessitating further investigation. However, only about 10% of those flagged actually result in a diagnosis of malignancy. Therefore, the overall annual yield of screening mammography is approximately **1 in 100 women (1%)**. **Analysis of Incorrect Options:** * **Option B (0.01%):** This value is far too low. It would imply that only 1 in 10,000 women screened has cancer, which would make mass screening programs clinically and economically non-viable. * **Option C & D (2% and 2.5%):** These figures overestimate the annual detection rate in a general screening population. While the *lifetime* risk of developing breast cancer is much higher (approx. 12% or 1 in 8), the *annual* detection rate via mammography remains steady at roughly 1%. **High-Yield Clinical Pearls for NEET-PG:** * **Sensitivity:** Mammography has a sensitivity of 70–90%. It is less sensitive in young women due to **dense breast tissue** (BI-RADS composition category C and D). * **BI-RADS Scoring:** Remember the management for BI-RADS 3 (Probably benign; 6-month follow-up), BI-RADS 4 (Suspicious; biopsy required), and BI-RADS 5 (Highly suggestive of malignancy; definitive action required). * **Screening Guidelines:** Most international guidelines recommend annual or biennial screening starting at age 40 or 50. * **Microcalcifications:** The most common mammographic sign of **Ductal Carcinoma in Situ (DCIS)** is pleomorphic microcalcifications.

Question 149: A 45-year-old woman presents with a hard and mobile lump in the breast. What is the next investigation?

A. Fine needle aspiration cytology (FNAC)
B. Ultrasound (USG)
C. Mammography (Correct Answer)
D. Excision biopsy

Explanation: ### Explanation The management of a breast lump follows the **Triple Assessment** protocol: Clinical Examination, Imaging, and Pathology (Biopsy). **Why Mammography is the correct answer:** In a woman aged **45 years**, the breast tissue is typically less dense and more fatty, making **Mammography** the gold-standard initial imaging modality. It helps characterize the lesion (looking for microcalcifications or spiculation) and screens the contralateral breast for occult lesions. In the NEET-PG context, the age cutoff for choosing Mammography over Ultrasound is generally **35 years**. Since this patient is 45, Mammography is the mandatory next step after clinical examination. **Analysis of Incorrect Options:** * **Fine Needle Aspiration Cytology (FNAC):** While part of the triple assessment, imaging should ideally precede tissue diagnosis to avoid hematomas that might interfere with radiological interpretation. Furthermore, Core Needle Biopsy (CNB) has largely replaced FNAC as the preferred pathological tool. * **Ultrasound (USG):** This is the investigation of choice for women **<35 years** (due to dense breasts) or to differentiate between cystic and solid lesions. In a 45-year-old, it is used as an adjunct to mammography, not the primary next step. * **Excision Biopsy:** This is an invasive procedure and is never the "next" step. It is only indicated if triple assessment is inconclusive or if the lesion is suspicious despite negative imaging/cytology. **Clinical Pearls for NEET-PG:** * **Triple Assessment Accuracy:** If all three components (Clinical, Imaging, Pathology) are concordant, the diagnostic accuracy is >99%. * **Age Cutoff:** <35 years = USG; >35 years = Mammography. * **BIRADS Scoring:** Used in mammography to standardize reporting (BIRADS 1-6). * **Gold Standard for Diagnosis:** Core Needle Biopsy (CNB) is superior to FNAC as it preserves tissue architecture and allows for IHC (ER/PR/HER2) testing.

Question 150: In breast conservative surgery, what is the typically healthy margin excised?

A. 1 cm (Correct Answer)
B. 2 cm
C. 3 cm
D. 5 cm

Explanation: **Explanation:** The goal of **Breast Conservative Surgery (BCS)**, such as lumpectomy or wide local excision, is to remove the primary tumor with a clear margin of healthy tissue while preserving the cosmetic appearance of the breast. **1. Why 1 cm is correct:** Traditionally, a **1 cm margin** of healthy tissue is excised circumferentially around the tumor to ensure "negative margins." In modern surgical oncology, the consensus (SSO-ASTRO guidelines) for invasive carcinoma is "no ink on tumor," meaning even a microscopic margin is acceptable. However, for the purpose of standard surgical practice and competitive exams like NEET-PG, **1 cm** remains the classic benchmark for a healthy macroscopic margin to minimize the risk of local recurrence. **2. Why other options are incorrect:** * **2 cm & 3 cm:** These margins are excessively large for BCS. Excising this much healthy tissue significantly compromises the cosmetic outcome, defeating the primary purpose of "conservation." * **5 cm:** This margin is historically associated with **Radical Mastectomies** or the excision of very large benign tumors (like Giant Fibroadenomas). In malignant cases, a 5 cm margin would essentially result in a mastectomy. **Clinical Pearls for NEET-PG:** * **Absolute Contraindications for BCS:** Multicentric disease, prior radiation to the breast/chest wall, pregnancy (first/second trimester), and persistent positive margins after re-excision. * **Mandatory Adjunct:** BCS must *always* be followed by **Radiotherapy** to the remaining breast tissue to reduce recurrence rates to levels comparable to a mastectomy. * **Margin Status:** For **DCIS (Ductal Carcinoma In Situ)**, a wider margin of **2 mm** is specifically recommended, whereas for invasive cancer, "no ink on tumor" is the standard.

Practice by Chapter

Breast Anatomy and Physiology

Practice Questions

Benign Breast Diseases

Practice Questions

Breast Cancer Screening

Practice Questions

Breast Cancer: Diagnosis and Staging

Practice Questions

Surgical Management of Breast Cancer

Practice Questions

Oncoplastic Breast Surgery

Practice Questions

Sentinel Lymph Node Biopsy

Practice Questions

Axillary Surgery

Practice Questions

Breast Reconstruction Techniques

Practice Questions

Male Breast Disorders

Practice Questions

Phyllodes Tumors

Practice Questions

Management of Ductal Carcinoma In Situ

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free